Methylphenidate treated at the test cage dose-dependent sensitization or tolerance depend on the behavioral assay used

Critical Reviews in Neurobiology

Volumn 19, Issue 1, 2007, Pages 59-77

  Yang, Pamela B ^a   Swann, Allan C ^a   Dafny, Nachum ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

ADHD; Dose response; Locomotor activity; Open field; Ritalin; Running wheel

Indexed keywords

METHYLPHENIDATE; SODIUM CHLORIDE; CENTRAL STIMULANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CAGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; LOCOMOTION; MALE; NONHUMAN; RAT; SENSITIZATION; ANALYSIS OF VARIANCE; ANIMAL; BEHAVIOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG EFFECT; EXPLORATORY BEHAVIOR; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIORAL SYMPTOMS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOLERANCE; EXPLORATORY BEHAVIOR; MALE; METHYLPHENIDATE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 64249107288     PISSN: 08920915     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevNeurobiol.v19.i1.20     Document Type: Article

References (52)

1. Askenasy ER, Taber KH, Yang PB, Dafny N. Methylphenidate (Ritalin): behavioral studies in the rat. Int J Neurosci. 2007;117:757-94.
2. Dafny N, Yang PB. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull. 2006;68:393-405.
3. Eichlseder W. Ten years of experience with 1.000 hyperactive children in a private practice. Pediatrics. 1985;76:176-81.
4. Gadow KD. An overview of three decades of research in pediatric psychopharmacoepidemiology. J Child Adolesc Psychopharmacol. 1997; 7:219-36.
5. Gatley SJ, Volkow ND, Gifford AN, Fowler JS, Dewey SL, Ding YS, Logan J. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacology. 1999; 146:93-100.
6. Rush CR, Baker RW. Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol. 2001;9:59-73.
7. Pierce CR, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev. 1997; 25:192-216.
8. Robinson TE. Persistent sensitizing effects of drugs on brain dopamine systems and behavior: implications for addiction and relapse. In: Korenman SG, Barchas JD, editors. Biological basis of substance abuse. New York: Oxford University Press; 1993. p. 373-402.
9. Wise RA. Action of drugs of abuse on brain reward system. Pharmacol Biochem Behav. 1980;13:213-23.
10. Kalivas PW. Interactions between dopamine and excitatory amino acids in behavioral sensitization to psychostimulants. Drug Alcohol Depend. 1995;37:95-100.
11. Karler R, Chaudhry IA, Calder LD, Turkanis SA. Amphetamine behavioral sensitization and the excitatory amino acids. Brain Res. 1990;537: 76-82.
12. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects. A review. Pharm Biochem Behav. 2001;68:611-27.
13. Robinson TE. Behavioral sensitization: characterization of enduring changes in rotational behavior produced by intermittent injections of amphetamine in male and female rats. Psychopharmacology (Berl) 1984; 84:466-75.
14. Robinson TE, Becker JB. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 1986;396:157-98.
15. Wolf ME. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol. 1998;54:679-720.
16. Stewart J, Badiani A. Tolerance and sensitization in the behavioral effects of drugs. Behav Pharmacol. 1993;4:289-312.
17. Berridge KC, Robinson TE. The mind of an addicted brain: neural sensitization of wanting versus liking. Curr Dir Psychol Sci. 1995;4:71-6.
18. Brandon CL, Marinelli M, Baker LK, White FJ. Enhanced reactivity and vulnerability to cocaine following methylphenidate treatment in adolescent rats. Neuropsychopharmacology. 2001;25:651-61.
19. Feldpausch DL, Needham LM, Stone MP, Althaus JS, Yamamoto BK, Svensson KA, Merchant KM. The role of dopamine D4 receptor in the induction of behavioral sensitization to amphetamine and accompanying biochemical and molecular adaptations. J Pharmacol Exp Ther. 1998; 286:497-508.
20. Crutchley A, Temlett JA. Methylphenidate (Ritalin) use and abuse. S Afr Med J. 1999;89:1076-9.
21. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbrid LE, Ruddon RW, Gilman AG, editors. Goodman's and Gilman's the pharmacological basis of therapeutics. New York: Pergamon; 1996. p. 199-250.
22. Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple Tic disorder. Pediatrics. 1999;103:730-7.
23. Karler R, Clader LD, Bedingfield JB. Cocaine behavioral sensitization and the excitatory amino acids. Psychopharmacology. 1994;115:305-10.
24. Lett BT. Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine and cocaine. Psychopharmacology. 1989;98:357-62.
25. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev. 1993;18:247-91.
26. Gatley SJ, Meehan SM, Ruoyan C, Dong-Feng P, Schechter MD, Dewey SL. Place preference and microdialysis studies with two derivatives of methylphenidate. Life Sci. 1996;58:345-52.
27. Meririnne E, Kankaanpää A, Seppälä T. Rewarding properties of methyl-phenidate: sensitization by prior exposure to the drug and effects of dopamine D1- and D2-receptor antagonists. J Pharmacol Exp Ther. 2001; 298:539-50.
28. Carrey N, McFadyen MP, Brown RE. Effects of subchronic methylpheni-date hydrochloride administration on the locomotor and exploratory behavior of prepubertal mice. J Child Adolesc Psychopharmacol. 2000; 10:277-86.
29. Gaytan O, Yang P, Swann A, Dafny N. Diurnal differences in sensitiza-tion to methylphenidate. Brain Res. 2000;864:24-39.
30. Gentsch C, Lichtsteiner M, Freer H. Open field and elevated plus-maze: a behavioural comparison between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats and the effects of chlordiazepoxide. Behav Brain Res. 1987;25:101-7.
31. Yang P, Singhal N, Modi G, Swann A, Dafny N. Effects of lithium chloride on induction and expression of methylphenidate sensitization. Eur J Pharmacol. 2001;426:65-72.
32. Yang PB, Amini B, Swann AC, Dafny N. Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res. 2003;971:139-52.
33. Gaytan O, Lewis C, Swann AC, Dafny N. Diurnal differences in amphetamine sensitization. Eur J Pharmacol. 1999;374:1-9.
34. Amini B, Yang PB, Swann AC, Dafny N. Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci. 2004;114:1063-84.
35. Chao JR, Nestler EJ. Molecular neurobiology of drug addiction. Annu Rev Med. 2004;55:118-32.
36. Nestler EJ. Molecular neurobiology of drug addiction. Neuropsycho-pharmacology. 1994;11:77-87.
37. Nestler EJ, Duman RG. Proteins and cyclic nucleotides in the nervous system. In: Siegel GI, Albert RW, Agranoff BW, Molinoff R, editors. Basic neurochemistry: molecular, cellular and medical aspects. 5th ed. Boston: Little Brown; 1994. p. 429-48.
38. Nestler EJ, Greengaard P. Protein phosphorylation and the regulation of neuronal function. In: Siegel GI, Albert RW, Agranoff BW, Molinoff P, editors. Brain neurochemistry: molecular, cellular and medical aspects. 5th ed. Boston: Little Brown; 1994. p. 449-74.
39. Phillips M, Wang C, Johnson MK. Pharmacological characterization of locomotor sensitization induced by chronic phencyclidine administration. J Pharmacol Exp Ther. 2001;296:905-13.
40. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fiebelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:1-15.
41. White SR, Yadao CM. Characterization of methylphenidate exposures reported to a regional poison control center. Arch Pediatr Adolesc Med. 2000;154:1199-203.
42. El-Zein RA, Abdel-Rahman SZ, Hay MJ, Lopez MS, Bondy ML, Morris DL, Legator MS. Cytogenic effects in children treated with methylphenidate. Cancer Lett. 2005;230:284-91.
43. Patrick KS, Markowitz JS. Pharmacology of methylphenidate, amphetamine enantiomers, and pemoline in attention deficit hyperactivity disorder. Hum Psychopharmacol (Berl). 1997;12:527-46.
44. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998;94:127-52.
45. Solanto MV. Clinical psychopharmacology of AD/HD: implications for animal models. Neurosci Biobehav Rev. 2000;24:27-30.
46. Spear LP, Brake SC. Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol. 1983;16:83-109.
47. Bowman BP, Kuhn CM. Age-related differences in the chronic and acute response to cocaine in the rat. Dev Psychobiol. 1996;29:597-611.
48. Brandon CL, Steiner H. Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur J Neurosci. 2003;18: 1584-92.
49. Faraj BA, Israili AH, Perel JM, Jenkins ML, Holtzman SG, Cucinell SA, Dayton PG. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J Pharmacol Exp Ther. 1974;191:535-47.
50. Santosh PJ, Taylor E. Stimulant drugs. Eur Child Adolesc Psychiatry. 2000;9:1-28.
51. Kuczenski R, Segal DS. Sensitization of amphetamine-induced stereotyped behaviors during the acute response. J Pharmacol Exp Ther. 1999; 288:699-709.
52. Wang GJ, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr G, Pascani K, Pappas N, Liu A, Cooper T, Lieberman JA. Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res. 1997;41:49-54.